A breakthrough in NSCLC therapy: targeted protein degradation of CD26 via PROTACs.
APA
Guan X, Yu XY, Zhang L (2026). A breakthrough in NSCLC therapy: targeted protein degradation of CD26 via PROTACs.. EBioMedicine, 123, 106082. https://doi.org/10.1016/j.ebiom.2025.106082
MLA
Guan X, et al.. "A breakthrough in NSCLC therapy: targeted protein degradation of CD26 via PROTACs.." EBioMedicine, vol. 123, 2026, pp. 106082.
PMID
41406503
같은 제1저자의 인용 많은 논문 (5)
- Discovery of a First-in-Class Murine Double Minute 2-Recruiting Positive Transcription Elongation Factor B PROTAC Degrader With Selective Antitumor Activity.
- Complement contributes to ICI-triggered sialadenitis and predicts ICI efficacy.
- Epigenome-wide association study of leukocyte telomere length and their effects on smoking-induced lung tumorigenesis: insights from the Dongfeng-Tongji cohort study.
- Enhanced chemiluminescence aptasensing with triple cascade amplification for sensitive detection of tumor-derived exosomes.
- The KANSL1-ARL17A fusion gene generates oncogenic chKANSARL and F-circKA RNAs that synergistically drive lung cancer progression via a novel F-circKA/miR-6860/chKANSARL axis.